loading page

RESPIRATORY FUNCTION RESPONSE IN PAEDIATRIC SPINAL MUSCULAR ATROPHY TYPES 2 AND 3 TREATED WITH NUSINERSEN
  • +4
  • Archana Chacko,
  • Peter Sly,
  • Robert Ware ,
  • Brett Dyer,
  • Sean Deegan,
  • Nicole Thomas,
  • Leanne Gauld
Archana Chacko
The University of Queensland Child Health Research Centre

Corresponding Author:[email protected]

Author Profile
Peter Sly
The University of Queensland Child Health Research Centre
Author Profile
Robert Ware
Griffith University Menzies Health Institute Queensland
Author Profile
Brett Dyer
Griffith University Menzies Health Institute Queensland
Author Profile
Sean Deegan
Queensland Children's Hospital
Author Profile
Nicole Thomas
Queensland Children's Hospital
Author Profile
Leanne Gauld
The University of Queensland Child Health Research Centre
Author Profile

Abstract

not-yet-known not-yet-known not-yet-known unknown Aim: To establish whether the initial positive effect of nusinersen (NUS) on respiratory outcomes in the first year of treatment was maintained in children with Spinal Muscular Atrophy (SMA) type 2 and to further define the effect on children with type 3 treated over 3 years. Methods: A prospective observational study of children with type 2 and 3 beginning NUS in Queensland, Australia between June 2018 – December 2020 was undertaken. Investigations conducted included age-appropriate lung function and polysomnography. Lung function data for two-years preceding NUS initiation was retrospectively collected. Change in lung function/polysomnography was assessed using mixed effects linear regression. Results: 24 of 30 children with type 2 and 3 SMA (14 males; 0.4-17.3 years) were included (type 2 n=12; type 3 n=12). No child had respiratory-related admissions during the period of study. For type 2, annual decline in FVC z-score pre-treatment was -0.75 (95% CI: -1.14, -0.39, p<0.001), and for the first 3 years on NUS was -0.20 ([95% CI: -0.33, -0.06, p=0.01] difference p=0.008). For type 3 minimal change was seen: pre-NUS and post FVC z-scores -0.20 (95% CI: -1.00, 0.61 p=0.05) and -0.46 (95% CI:-0.88, -0.04 p=0.40) respectively (difference p=0.46). Mean change in total apnoea-hypopnoea indices (total AHI) in type 2 tended to reduce -1.75 (95% CI: -4.95-0.9, p=0.24); type 3 appeared to remain stable (-0.39 [95% CI: -1.1-0.33, p=0.28). One child with type 2 ceased NIV due to normalisation of total AHI and gas exchange. Conclusion: Nusinersen lung function (FVC-z-scores) stability seen in the first year was maintained over 3 years and the total AHI tended to improve in type 2, but the long-term effects in type 3 are less clear.